0001601830-24-000127.txt : 20240819
0001601830-24-000127.hdr.sgml : 20240819
20240819190942
ACCESSION NUMBER: 0001601830-24-000127
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240815
FILED AS OF DATE: 20240819
DATE AS OF CHANGE: 20240819
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mauro David J
CENTRAL INDEX KEY: 0001621172
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40323
FILM NUMBER: 241222229
MAIL ADDRESS:
STREET 1: 36 TERRELL DRIVE
CITY: WASHINGTON CROSS
STATE: PA
ZIP: 18977
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
4
1
wk-form4_1724108977.xml
FORM 4
X0508
4
2024-08-15
0
0001601830
RECURSION PHARMACEUTICALS, INC.
RXRX
0001621172
Mauro David J
41 S. RIO GRANDE STREET
SALT LAKE CITY
UT
84101
0
1
0
0
Chief Medical Officer
0
Class A Common Stock
2024-08-15
4
F
0
14146
6.69
D
229616
D
Stock Option (Right to Buy)
10.09
2034-02-09
Class A Common Stock
0
99537
D
Stock Option (Right to Buy)
8.77
2033-06-01
Class A Common Stock
0
381426
D
Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
This option vests as to one fourth (1/4th) of the shares subject to the option on June 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.
/s/Jonathan Golightly, attorney-in-fact
2024-08-19